WO2015043497A1 - 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品 - Google Patents

一种多肽疫苗的盐及其制备方法和含有该盐的药物制品 Download PDF

Info

Publication number
WO2015043497A1
WO2015043497A1 PCT/CN2014/087506 CN2014087506W WO2015043497A1 WO 2015043497 A1 WO2015043497 A1 WO 2015043497A1 CN 2014087506 W CN2014087506 W CN 2014087506W WO 2015043497 A1 WO2015043497 A1 WO 2015043497A1
Authority
WO
WIPO (PCT)
Prior art keywords
kifgslafl
acetate
salt
solution
purity
Prior art date
Application number
PCT/CN2014/087506
Other languages
English (en)
French (fr)
Inventor
谭端明
田茂奎
孙宝金
Original Assignee
深圳信立泰药业股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 深圳信立泰药业股份有限公司 filed Critical 深圳信立泰药业股份有限公司
Priority to JP2016518164A priority Critical patent/JP6392330B2/ja
Priority to CA2925535A priority patent/CA2925535A1/en
Priority to EP14850072.1A priority patent/EP3050895A4/en
Priority to KR1020167007821A priority patent/KR101802485B1/ko
Priority to RU2016114322A priority patent/RU2649401C2/ru
Priority to US15/023,805 priority patent/US20160229891A1/en
Publication of WO2015043497A1 publication Critical patent/WO2015043497A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the invention belongs to the technical field of pharmacy, and relates to a polypeptide vaccine salt and a preparation method thereof, in particular to KIFGSLAFL acetate salt, a preparation method thereof and a pharmaceutical product containing the salt.
  • BCa Breast cancer
  • DFS disease-free survival
  • antibody therapies that are responsive to tumor-associated antigens have been used to block specific cellular processes to slow disease progression or prevent disease recurrence.
  • a significant number of patients will eventually die from recurrent disease. Therefore, there is a need for treatment that prevents or slows or inhibits the occurrence of recurrent diseases.
  • Vaccines are attractive models of treatment and prevention because of their ease of administration and because of the high success rates they observe in infectious diseases.
  • the basic principles of building a cancer vaccine are theoretically straightforward. In practice, however, the development of effective solid tumor cancer vaccines has had limited success.
  • KIFGSLAFL (a nonapeptide of amino acid sequence composition Lys-Ile-Phe-Gly-Ser-Leu-Ala-Phe-Leu, also known as HER2/neu 369-377, is a peptide sequence of the HER2/neu proto-oncogene family.
  • Vaccines with cytotoxic T lymphocyte (CTL) response pre-use for the prevention and/or treatment of cancer, are currently being used for clinical laboratory studies (Zaks T et al., Immunization with a peptide epitope (369-377) from HER-2/neu leads to peptide specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+tumors, Cancer Research, 1998, 58(21): 4902-8; Knutson KL et al., Immunization of cancer patients with HER- 2/neu, HLA-A2 peptide, p369-377, notes in short-lived peptide-specific immunity, Clin Cancer Res 2002, 8(5): 1014-1018.
  • CTL cytotoxic T lymphocyte
  • the KIFGSLAFL sample used in the clinical trials disclosed in the prior art is in the DMSO solution state, has poor stability at room temperature, needs to be stored at a low temperature of -20 ° C, and is thawed before use. No reports of compounds or mixtures of this polypeptide that are stable at room temperature have been reported to date.
  • One of the objects of the present invention is to provide KIFGSLAFL acetate which greatly improves the purity, water solubility and stability of the raw materials.
  • the KIFGSLAFL refers to a nonapeptide having an amino acid sequence of the following composition:
  • the KIFGSLAFL acetate formula is C 50 H 78 N 10 O 11 ⁇ C 2 H 4 O 2 .
  • the above KIFGSLAFL acetate is prepared by the preferred method of the present invention and has a very high medicinal purity, purity ⁇ 95%, still more preferably ⁇ 98%, particularly preferably ⁇ 99%. It is of great significance for ensuring the effectiveness and safety of drugs and has good commercial development value.
  • the method for preparing KIFGSLAFL acetate obtained by a large number of experiments in the present invention comprises the following steps:
  • the KIFGSLAFL peptide resin was synthesized by Fmoc solid phase synthesis method according to the amino acid sequence (9 ⁇ 1), and then cleaved by trifluoroacetic acid to obtain crude KIFGSLAFL, which specifically includes the following steps:
  • Fmoc-protected amino acids further reacted with Leu-resin are: Fmoc-Phe-OH, Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gly-OH, Fmoc- Phe-OH, Fmoc-Ile-OH, Fmoc-Lys(Boc)-OH.
  • the condensing agent preferably includes HATU, HBTU, BOP, PyBOP, DIC/HOBt, DIC/HOAt, and the like.
  • the trifluoroacetic acid cleavage solution means that 50-95% (v/v) of trifluoroacetic acid is contained, and the balance is dichloromethane, or 1-10% (v/v) of water, phenol, p-methylphenol may be further added.
  • a carbon cation trapping agent such as anisole, thioanisole, 1,2-ethanedithiol or triisopropylsilane (TIS).
  • the crude KIFGSLAFL prepared by the method (1) is dissolved in a mixed solution of acetonitrile and water, filtered, and the filtrate is purified by reverse-phase high performance liquid chromatography to obtain a pure acetonitrile/water solution.
  • the purification conditions of the reversed-phase high performance liquid chromatography are preferably C4, C8, C18 alkyl bonded silica gel as a stationary phase, further preferably C18 alkyl bonded silica gel; column temperature is preferably 20-35 ° C, further preferably 25-30 ° C; mobile phase It is an acetonitrile/water solution containing trifluoroacetic acid having a trifluoroacetic acid concentration of 0.02% to 0.5% (v/v), preferably 0.05% to 0.2% (v/v).
  • the volume percentage of acetonitrile in the mobile phase is preferably from 10% to 80%, eluted from a low concentration to a high concentration gradient, further preferably from 20% to 50%.
  • the pure KIFGSLAFL solution prepared by the above method (2) was treated with reverse phase high performance liquid chromatography using an acetonitrile/water solution of acetic acid as a mobile phase to obtain a KIFGSLAFL acetate solution.
  • the reverse-phase high performance liquid chromatography used for the salt-transfer condition is preferably a C4, C8, C18 alkyl-bonded silica gel as a stationary phase, further preferably a C18 alkyl-bonded silica gel;
  • the column temperature is preferably 20-35 ° C, further preferably 25-30 ° C;
  • the mobile phase is an acetonitrile/water solution containing acetic acid having a concentration of acetic acid of from 0.02% to 0.5% (v/v), preferably from 0.05% to 0.2% (v/v).
  • the volume percentage of acetonitrile in the mobile phase is preferably from 2% to 80%, and is eluted from a low concentration to a high concentration gradient, and it is further preferred to first elute at least one column volume with a 2% to 4% isocratic or gradient, and then use 20% to 50%. % elutes from a low to high gradient.
  • One method is that the KIFGSLAFL acetate solution obtained by the above method (3) can be concentrated under reduced pressure and dried to obtain KIFGSLAFL acetate solid.
  • the KIFGSLAFL acetate solution prepared by the above method (3) can be concentrated under reduced pressure to precipitate a KIFGSLAFL acetate precipitate, and the precipitate is obtained by centrifugation, and the precipitate is vacuum dried to obtain a KIFGSLAFL acetate solid.
  • Another object of the present invention is to provide KIFGSLAFL acetate which is an amorphous solid whose X-ray diffraction spectrum has no absorption peak of crystal characteristics.
  • the amorphous solid KIFGSLAFL acetate can significantly improve water solubility and stability, and is easier to use for pharmaceutical preparations, particularly for administration by injection.
  • the method for preparing an amorphous solid KIFGSLAFL acetate obtained by a large number of experiments in the present invention comprises the following steps:
  • the KIFGSLAFL acetate solution prepared by the above method (3) is adjusted to pH about 4 with acetic acid, and the KIFGSLAFL acetate precipitate is concentrated and concentrated under reduced pressure, and the temperature is lowered to below 5 ° C, and the precipitate is obtained by centrifugation, and dried under vacuum at ⁇ 30 ° C. A homogeneous KIFGSLAFL acetate amorphous solid was obtained.
  • the X-ray diffraction spectrum was detected by the following method: instrument model: Empyean X-ray diffractometer; test conditions: Cu target K ⁇ 1 ray, voltage 40kv, electricity
  • the flow is 40 mA
  • the 2 ⁇ range is 3°-50°
  • the divergence slit is 1/32°
  • the anti-scatter slit is 1/16°
  • the anti-scatter slit is 7.5 mm
  • the step length is 0.02°
  • the dwell time per step is 40S.
  • the amorphous solid KIFGSLAFL acetate was detected by ESI mass spectrometry and its molecular ion peak was 995.9, which was basically consistent with the molecular weight calculated by KIFGSLAFL.
  • the mobile phase A is acetonitrile
  • the mobile phase B is 0.1 mol/L sodium dihydrogen phosphate (pH adjusted to 3.0 with phosphoric acid) aqueous solution
  • gradient elution mobile phase A from 5% to 45%, elution time 20 min; then change the mobile phase A45% isocratic elution
  • flow rate 1 mL/min.
  • the detection wavelengths were 195 nm (0-8 min) and 230 nm (8-50 min).
  • the peak times of acetic acid and the target peptide KIFGSLAFL were about 4.6 and 21 min, respectively.
  • a further object of the present invention is to provide a pharmaceutical preparation of a polypeptide vaccine comprising the aforementioned KIFGSLAFL acetate which is suitably reconstituted as an injectable pharmaceutical product with a pharmaceutically acceptable vehicle, which is administered to the patient by injection.
  • the pharmaceutically acceptable vehicle includes water for injection, sterile water, and the like.
  • the KIFGSLAFL acetate of the present invention especially its amorphous solid, has good purity and stability, as well as superior water solubility, greatly improving the efficacy and safety of the pharmaceutical preparation.
  • the pharmaceutical product may or may not contain more than one pharmaceutically acceptable excipient.
  • the pharmaceutical preparation of the present invention may be in any powder form for parenteral administration, such as lyophilized powder, suspension type, dairy injection, and the like.
  • the pharmaceutical preparations are preferably used to treat breast cancer and breast cancer recurrence.
  • the KIFGSLAFL acetate in the present invention refers to KIFGSLAFL acetate having a molecular formula of C 50 H 78 N 10 O 11 ⁇ C 2 H 4 O 2 .
  • the present invention has the following outstanding advantages and beneficial effects:
  • the KIFGSLAFL acetate provided by the invention greatly improves the purity, stability and water solubility of the drug relative to KIFGSLAFL and KIFGSLAFL sulfate, and fully ensures the safety and effectiveness of the medicament.
  • the amorphous solid KIFGSLAFL acetate provided by the invention has excellent water solubility and stability, and is easy to be reconstituted by the drug when it is easy to be administered by injection, compared with the injection solvent.
  • the KIFGSLAFL acetate solution in the dissolved state (such as dimethyl sulfoxide) has better stability. According to its dissolution and stability properties, it is more favorable for the preparation of the medicament, which can fully ensure the convenient use of the pharmaceutical preparation, and the safety of the medicine. And effective.
  • the invention provides a preparation method of high-purity KIFGSLAFL acetate, which overcomes the technical difficulties of preparing salt and improving purity in the prior art.
  • the method has mild conditions, is easy to reproduce, and greatly reduces the industrialization cost.
  • step 2 the next amino acid is coupled in turn.
  • the subsequent amino acid sequence and amount were: Fmoc-Ala-OH 19.9 g, Fmoc-Leu-OH 22.6 g, Fmoc-Ser(tBu)-OH 24.5 g, Fmoc-Gly-OH 19.0 g, Fmoc-Phe-OH 24.8 g, Fmoc-Ile-OH 22.6 g and Fmoc-Lys(Boc)-OH 30.0 g.
  • the conditions for the determination of the purity of the target peptide by high performance liquid chromatography were as follows: Innovative Tongheng LC300 high performance liquid chromatography, C18 bonded silica gel (250 ⁇ 4.6 mm, 5 ⁇ m) as the stationary phase, mobile phase 0.1 mol/L sodium dihydrogen phosphate (Polyphosphoric acid adjusted to 3.0) A mixture of aqueous solution and acetonitrile (volume ratio 7:3). The flow rate was 1 mL/min. The detection wavelength was 230 nm. The peak time of the target peptide was about 10 min.
  • the KIFGSLAFL solution obtained in Example 2 was cooled to 0-5 ° C, and a 5% aqueous NaOH solution was added dropwise to pH 10 with stirring. Concentrate under reduced pressure to precipitate a large amount of a gelatinous precipitate. Centrifuge and wash with a small amount of ice water. The precipitate was dried in vacuo to give a white solid (yield: 98.1%).
  • the KIFGSLAFL solution obtained in Example 2 was appropriately concentrated and then purified by a C18 column with a packing height of 250 mm and a diameter of 150 mm. It was first eluted with an aqueous solution containing 0.1% by volume of acetic acid and 3% by volume of acetonitrile for 15 min at a flow rate of 800 mL/min. Then, mobile phase A was used as water containing 0.1% by volume of acetic acid, mobile phase B was acetonitrile containing 0.1% by volume of acetic acid, and gradient elution (B: 20% - 40%, elution time 50 min), and the detection wavelength was 230 nm. The main peak component was collected to obtain a KIFGSLAFL acetate solution having a purity of 99.6% and a yield of 90%.
  • the KIFGSLAFL acetate solution obtained in Example 4 was adjusted to pH 4 with acetic acid, concentrated under reduced pressure to precipitate a large amount of colloidal precipitate, cooled to 0-5 ° C, and precipitated by centrifugation, and the precipitate was vacuum dried at ⁇ 30 ° C to obtain a white solid. .
  • the peak time of acetic acid was about 4.6 min.
  • the weight percentage of acetic acid in the sample was determined to be 5.7%.
  • the purity of KIFGSLAFL is 99.5%.
  • X-ray diffraction spectrum detection conditions instrument model: Sharp (Empyrean) X-ray diffractometer; test conditions: Cu target K ⁇ 1 ray, voltage 40kv, current 40mA, 2 ⁇ range 3°-50°, divergence slit 1/32 °, anti-scatter slit 1/16°, anti-scatter slit 7.5mm, step size 0.02°, 40S per step.
  • instrument model Sharp (Empyrean) X-ray diffractometer
  • test conditions Cu target K ⁇ 1 ray, voltage 40kv, current 40mA, 2 ⁇ range 3°-50°, divergence slit 1/32 °, anti-scatter slit 1/16°, anti-scatter slit 7.5mm, step size 0.02°, 40S per step.
  • the X-ray diffraction spectrum is shown in Figure 1.
  • Sample 1 was the amorphous solid product of Example 5.
  • Sample 2 was dilute to a solution of Example 4 with dimethyl sulfoxide to about 1 mg/mL and filtered through a 0.2 micron pore size filter.
  • Sample 3 was the solid product of Example 3.
  • Sample 4 was the solid product of Example 3 dissolved in dimethyl sulfoxide and diluted to about 1 mg/mL and filtered through a 0.2 micron pore size filter.
  • Sample 5 was the solid product of Example 6. The purity of each sample was determined by high performance liquid chromatography, and the results are as follows:
  • Example 3 Example 5 and Example 6 were respectively added to a certain amount of water for injection at 25 ° C, and shaken in a constant temperature shaker to observe the dissolution of the solid.
  • the dissolution is as follows:
  • Example 3 sample Example 5 sample Example 6 sample 300 times >30 minutes (not fully dissolved) ⁇ 1 minute (full solution) >30 minutes (not fully dissolved) 800 times >30 minutes (not fully dissolved) ⁇ 1 minute (full solution) >30 minutes (not fully dissolved)
  • the KIFGSLAFL acetate salt was prepared as described in Example 5 in a sterile environment. Precision weighing (1mg/part in KIFGSLAFL), packaged in glass bottles, sealed in a package, to obtain a peptide vaccine product.
  • the KIFGSLAFL solution obtained in Example 2 was appropriately concentrated and then purified by a C18 column with a packing height of 250 mm and a diameter of 150 mm.
  • the mobile phase A was water containing 0.1% by volume of acetic acid
  • the mobile phase B was acetonitrile
  • the gradient was eluted (B: 20%-40%, elution time 50 min), the flow rate was 800 mL/min, and the detection wavelength was 230 nm.
  • the main peak fraction was collected, and a solution of KIFGSLAFL was concentrated under reduced pressure and lyophilized to give a white solid.
  • the weight percentage of acetic acid was 4.8% and the weight percentage of trifluoroacetic acid was 1.9% as determined by HPLC of Example 2.
  • the crude KIFGSLAFL obtained in Example 1 was chromatographed according to the method of Example 2 to collect the main peak component.
  • the purity of the collected liquid was measured by analytical high performance liquid chromatography.
  • the KIFGSLAFL solution was obtained by combining fractions having a purity greater than 92%.
  • the purity of the collected liquid was determined by analytical high performance liquid chromatography with a purity of 95.1%.
  • the salt was transferred according to the chromatographic method of Example 4, and the main peak component was collected to obtain a KIFGSLAFL acetate solution having a purity of 95.3%.
  • the obtained KIFGSLAFL acetate solution was concentrated to dryness under reduced pressure and dried under vacuum at 40 ° C to give a white solid.
  • the total yield is 60%.
  • the purity of KIFGSLAFL was 94.1% as determined by HPLC of Example 2.
  • the crude KIFGSLAFL obtained in Example 1 was chromatographed according to the method of Example 2 to collect the main peak component.
  • the purity of the collected liquid was measured by analytical high performance liquid chromatography.
  • the KIFGSLAFL solution was obtained by combining fractions having a purity greater than 92%.
  • the purity of the collected liquid was determined by analytical high performance liquid chromatography with a purity of 95.1%.
  • the salt was transferred according to the chromatographic method of Example 4, and the main peak component was collected to obtain a KIFGSLAFL acetate solution having a purity of 95.3%.
  • the total yield is 60%. It was then treated in the same manner as in Example 5 to give a white solid as an amorphous KIFGSLAFL acetate with a purity of 95.3%.
  • the crude KIFGSLAFL obtained in Example 1 was chromatographed according to the method of Example 2 to collect the main peak component.
  • the purity of the collected liquid was measured by analytical high performance liquid chromatography.
  • the fractions having a purity greater than 96% were combined to obtain a KIFGSLAFL solution.
  • the purity of the collected solution was determined by analytical high performance liquid chromatography with a purity of 97.5%.
  • the salt was transferred according to the chromatographic method of Example 4, and the main peak component was collected to obtain a KIFGSLAFL acetate solution having a purity of 98.1%.
  • the total yield was 45%.
  • KIFGSLAFL salt has obvious technical difficulty, and it is difficult to obtain a pure pure salt of high purity, and as described in the above Example 10, the synthetic product is easy to form a mixed salt such as acetic acid and trifluoroacetic acid, and it is difficult to separate and purify the single salt. Pure.
  • the inventors according to the conventional separation and purification means in the art can only obtain a product having a purity of less than 95%, which is disadvantageous for the medical application of the product.
  • the purity of the product is over 95%, and even more than 98%, overcoming the difficulty of obtaining high-purity KIFGSLAFL salt, making the product industry Chemical and medical applications are really possible.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明提供了多肽KIFGSLAFL的醋酸盐及其制备方法和含有该盐的药物制品。

Description

一种多肽疫苗的盐及其制备方法和含有该盐的药物制品 技术领域
本发明属于制药技术领域，涉及一种多肽疫苗盐及其制备方法，特别是涉及KIFGSLAFL醋酸盐及其制备方法和含有该盐的药物制品。
背景技术
乳腺癌(BCa)是女性最常见的癌症诊断并且是女性中与癌症相关死亡的第二主导因素(RiesLAG等人，SEER Cancer Statistics Review，1975-2003，National Cancer Institute，Bethesda，MD)。过去20年间在乳腺癌治疗中的主要进展使得无疾病生存(DFS)率显著提高。例如，已经将利用对肿瘤相关抗原有反应性的抗体疗法用于阻断特定的细胞过程以减缓疾病进展或者预防疾病复发。尽管近来在乳腺癌治疗上有所进展，但是相当数量的患者最终将死于复发疾病。因此，需要预防或者减缓或者抑制复发疾病的发生的治疗。
疫苗由于易于给药，以及因为他们在感染性疾病中观察到的高成功率而是对此种治疗和预防引人注意的模型。构建癌症疫苗的基本原理在理论上是直接的。然而实践中，有效的实体瘤癌症疫苗的开发仅存有限的成功。
KIFGSLAFL(氨基酸序列组成为Lys-Ile-Phe-Gly-Ser-Leu-Ala-Phe-Leu的九肽，也称之为HER2/neu 369-377，是HER2/neu原癌基因家族的肽序列，具有细胞毒性T淋巴细胞(CTL)应答作用，预用于预防和/或治疗癌症的疫苗，目前正在相关的用于临床实验研究(Zaks T等人,Immunization with a peptide epitope(369-377)from HER-2/neu leads to peptide specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+tumors,Cancer Research,1998,58(21)：4902-8；Knutson KL等人,Immunization of cancer patients with HER-2/neu，HLA-A2peptide，p369-377，fesults in short-lived peptide-specific immunity,Clin Cancer Res 2002,8(5):1014-1018。
然而，现有技术公开的临床试验使用的KIFGSLAFL样品是DMSO溶液状态，在室温下稳定性差，需要在-20℃低温保存，使用前再解冻。至今未见该多肽室温稳定的化合物或混合物报道。
发明内容
本发明的目的之一在于提供KIFGSLAFL醋酸盐，大幅改善原料纯度、水溶性和稳定性。
其中，所述KIFGSLAFL是指氨基酸序列为以下组成的九肽：
Lys-Ile-Phe-Gly-Ser-Leu-Ala-Phe-Leu
1 5 9
也称之为HER2/neu 369-377，所述KIFGSLAFL醋酸盐分子式为C50H78N10O11·C2H4O2。
上述KIFGSLAFL醋酸盐通过本发明的优选方法制备得到，具有非常高的药用纯度，纯度≥95％，还可进一步优选达到≥98％，特别优选纯度≥99％。对于保证药物的有效性和安全性具有重要意义，具有良好的商业开发价值。
因合成KIFGSLAFL过程中产生数量众多的杂质，使制备高纯度的KIFGSLAFL盐存在明显的技术难度，难以得到高纯度的单盐纯品。
本发明通过大量实验优选得到的制备KIFGSLAFL醋酸盐的方法，包括以下步骤：
(1)、KIFGSLAFL粗品的制备
采用Fmoc固相合成方法，按照氨基酸序列(9→1)的顺序，合成制备KIFGSLAFL肽树脂，然后经三氟乙酸裂解，得到KIFGSLAFL粗品，具体包括以下步骤：
(1.1)、以连接有Fmoc-Leu-OH的酸性敏感树脂(如Wang树脂或者2-氯-三苯甲基-树脂)为原料，与哌啶溶液反应，脱去Fmoc保护基，溶剂洗涤后得到Leu-树脂。
(1.2)、按照固相多肽合成的方法，Leu-树脂依次与Fmoc保护的氨基酸反应，获得九肽KIFGSLAFL-树脂。期间依次使用常用的缩合剂进行接肽反应，经溶剂洗涤后用哌啶溶液脱去Fmoc保护基，经溶剂洗涤后再进行下一个Fmoc保护的氨基酸的缩合。
与Leu-树脂进一步缩合反应的Fmoc保护的氨基酸依次为：Fmoc-Phe-OH、Fmoc-Ala-OH、Fmoc-Leu-OH、Fmoc-Ser(tBu)-OH、Fmoc-Gly-OH、Fmoc-Phe-OH、Fmoc-Ile-OH、Fmoc-Lys(Boc)-OH。
缩合剂优选包括HATU、HBTU、BOP、PyBOP、DIC/HOBt、DIC/HOAt等。
(1.3)、用三氟乙酸裂解溶液处理KIFGSLAFL-树脂，得到KIFGSLAFL的三氟乙酸溶液。加入乙醚析出沉淀，经离心和洗涤后得到KIFGSLAFL粗品。
三氟乙酸裂解溶液是指含有50-95％(v/v)的三氟乙酸，其余为二氯甲烷，或可进一步加入1-10％(v/v)的水、苯酚、对甲基酚、苯甲醚、苯甲硫醚、1,2-乙二硫醇、三异丙基硅烷(TIS)等碳正离子俘获试剂。
(2)、KIFGSLAFL的纯化
将方法(1)制备得到的KIFGSLAFL粗品溶解乙腈和水的混合溶液中，过滤，滤液用反相高效液相色谱纯化，得纯品的乙腈/水溶液。
反相高效液相色谱的纯化条件优选C4、C8、C18烷基键合硅胶为固定相，进一步优选C18烷基键合硅胶；柱温优选20-35℃，进一步优选25-30℃；流动相为含有三氟乙酸的乙腈/水溶液，其中三氟乙酸浓度为0.02％-0.5％(v/v)，优选0.05％-0.2％(v/v)。流动相中乙腈的体积百分比优选10％至80％，由低浓度向高浓度梯度洗脱，进一步优选从20％至50％。
(3)、转盐(成醋酸盐)
将上述方法(2)制得的KIFGSLAFL纯品溶液用醋酸的乙腈/水溶液为流动相的反相高效液相色谱处理，得到KIFGSLAFL醋酸盐溶液。
转盐条件采用的反相高效液相色谱优选C4、C8、C18烷基键合硅胶为固定相，进一步优选C18烷基键合硅胶；柱温优选20-35℃，进一步优选25-30℃；流动相为含有乙酸的乙腈/水溶液，其中乙酸浓度为0.02％-0.5％(v/v)，优选0.05％-0.2％(v/v)。流动相中乙腈的体积百分比优选2％至80％，由低浓度向高浓度梯度洗脱，进一步优选先用2％至4％等度或梯度洗脱至少一个柱体积，再用20％至50％由低到高梯度洗脱。
(4)、去除溶剂得到KIFGSLAFL醋酸盐固体。
一种方法是可将上述方法(3)制得的KIFGSLAFL醋酸盐溶液减压浓缩和干燥，得到KIFGSLAFL醋酸盐固体。
另一种方法可以把上述方法(3)制得的KIFGSLAFL醋酸盐溶液减压浓缩，析出KIFGSLAFL醋酸盐沉淀，离心取得沉淀，沉淀经真空干燥得KIFGSLAFL醋酸盐固体。
本发明的另一目的之一在于所提供KIFGSLAFL醋酸盐为无定形固体，其X-射线衍射谱图无晶体特征的吸收峰。无定形固体的KIFGSLAFL醋酸盐可明显提高水溶性和稳定性，更易于药物的制剂，特别是注射给药制剂的使用。
本发明通过大量实验优选得到的制备无定形固体KIFGSLAFL醋酸盐的方法，包括以下步骤：
将上述方法(3)制得的KIFGSLAFL醋酸盐溶液，用醋酸调节pH至4左右，减压浓缩析出KIFGSLAFL醋酸盐沉淀，降温至5℃以下，离心取得沉淀，经<30℃真空干燥后得到均匀的KIFGSLAFL醋酸盐无定形固体。
其中，X-射线衍射谱图通过采用如下方法检测得到，仪器型号：锐影(Empyrean)X-射线衍射仪；测试条件：Cu靶Kα1射线，电压40kv，电 流40mA，2θ范围3°-50°，发散狭缝1/32°，防散射狭缝1/16°，防散射狭缝7.5mm，步长0.02°，每步停留时间40S。
所述无定形固体的KIFGSLAFL醋酸盐采用KBr压片法IR光谱检测条件检测，其红外吸收在3288cm-1、3065cm-1、2958cm-1、1632cm-1、1527cm-1、1404cm-1和698cm-1处有峰。
所述无定形固体的KIFGSLAFL醋酸盐采用ESI质谱检测，其分子离子峰为995.9，与KIFGSLAFL的分子量计算值基本一致。
将KIFGSLAFL醋酸盐无定形固体用乙腈和水(体积比＝5：95)混合溶液溶解，采用以下高效液相色谱检测条件分析：C18键合硅胶(250×4.6mm，5μm)为固定相，流动相A为乙腈，流动相B为0.1mol/L磷酸二氢钠(磷酸调pH至3.0)水溶液，梯度洗脱(流动相A从5％到45％，洗脱时间20min；然后改流动相A45％等度洗脱)，流速1mL/min。检测波长195nm(0-8min)和230nm(8-50min)。醋酸和目标肽KIFGSLAFL的出峰时间分别约为4.6和21min。
本发明的再一目的在于提供一种多肽疫苗的药物制品，包含前述的KIFGSLAFL醋酸盐，它适宜用药学上可接受的溶媒重新配制为一种可注射的药用产品，通过注射途径给予患者。所述药学上可接受的溶媒包括注射用水、无菌水等。
因本发明的KIFGSLAFL醋酸盐，特别是其无定形固体具有良好的纯度和稳定性，以及优越的水溶性，极大的提高了该药物制品的用药有效性和安全性。
所述药物制品可以含有或者不含有一种以上的可药用的赋形剂。本发明的药物制品可以是非胃肠道给药的任何粉末形式，例如冻干粉末、混悬型、乳制品注射剂等。
所述药物制品可优选用于治疗乳腺癌及乳腺癌复发。
本发明中的KIFGSLAFL醋酸盐，除有特别指定外，均是指分子式为 C50H78N10O11·C2H4O2的KIFGSLAFL醋酸盐。
本发明各试剂的缩写为如下定义：
Fmoc 9-芴甲氧羰基
DMF N,N-二甲基甲酰胺
HATU 2-(7-氮杂苯并三氮唑)-N,N,N',N'-四甲基脲六氟磷酸酯
HBTU 苯并三氮唑-N,N,N',N'-四甲基脲六氟磷酸盐
BOP 苯并三氮唑-1-基氧基三(二甲基氨基)磷鎓六氟磷酸盐
PyBOP 六氟磷酸苯并三唑-1-基-氧基三吡咯烷基磷
HOBt 1-羟基苯并三唑
HOAt N-羟基-7-氮杂苯并三氮唑
DIC N,N-二异丙基碳二亚胺
tBu 叔丁基
TFA 三氟醋酸
TIS 三异丙基硅烷
v/v 相同度量单位的体积百分比，如mL/mL×100％
本发明与现有技术相比具有如下突出的优点及有益效果：
1、本发明提供的KIFGSLAFL醋酸盐，相对于KIFGSLAFL、KIFGSLAFL硫酸盐极大地提高药物纯度、稳定性和水溶性，充分保证药用安全和有效性。
2、本发明提供的无定形固体的KIFGSLAFL醋酸盐，具有优异水溶性和稳定性，易于注射给药等途径使用时的药物快速复溶，相对于注射溶剂 (如二甲基亚砜)溶解状态的KIFGSLAFL醋酸盐溶液具有更好的稳定性，根据其溶解及稳定性质，其属于更利于制备药剂的形式，可充分保证药物制剂的方便使用，用药安全和有效。
3、本发明提供了一种高纯度KIFGSLAFL醋酸盐的制备方法，克服现有技术制盐和提高纯度的技术困难，该方法条件温和，易于重现，大幅降低产业化成本。
附图说明
图1，KIFGSLAFL醋酸盐无定形固体的X-ray衍射光谱图。
图2，KIFGSLAFL醋酸盐无定形固体的IR光谱图。
图3，KIFGSLAFL醋酸盐无定形固体的ESI质谱检测谱图。
实施方式
以下实施例和附图用于解释本发明，但决不限制本发明。
实施例1、KIFGSLAFL粗品的制备
1、称取Fmoc-Leu-Wang树脂(取代度为0.8mmol/g)40g，加入DMF300mL溶胀树脂30min。抽滤去DMF，加入20％哌啶/DMF溶液300mL反应30min。抽滤，用DMF 6×150mL洗涤树脂。
2、加入Fmoc-Phe-OH 24.8g，HOBt 8.6g和DMF 150mL，搅拌均匀，再加入DIC 9.5mL，于28-30℃水浴中搅拌4～5h。经Kaiser法检测，树脂呈无色后，抽滤，用DMF 2×200mL洗涤树脂。加入20％哌啶/DMF溶液300mL反应30min，抽滤，用DMF 6×200mL洗涤树脂。
3、参考步骤2，依次偶联下一个氨基酸。后续氨基酸顺序及用量为：Fmoc-Ala-OH 19.9g，Fmoc-Leu-OH 22.6g，Fmoc-Ser(tBu)-OH 24.5g，Fmoc-Gly-OH 19.0g，Fmoc-Phe-OH 24.8g，Fmoc-Ile-OH 22.6g和Fmoc-Lys(Boc)-OH 30.0g。
4、依次用二氯甲烷和甲醇洗涤树脂，真空干燥，得KIFGSLAFL肽树脂。
5、称取10g肽树脂，加入100mL裂解溶液(TFA/TIS/H2O＝95/2.5/2.5，v/v/v)，室温搅拌2h。过滤树脂，适量裂解溶液洗涤树脂。洗涤液与滤液合并，搅拌下加入乙醚1L，析出沉淀。经离心和乙醚洗涤几遍后，真空干燥得到KIFGSLAFL粗品。
实施例2、KIFGSLAFL的纯化
将实施例1得到的KIFGSLAFL粗品5g溶解在100mL含有10％体积比乙腈的水中，过滤。滤液用C18柱纯化，填料高度250mm，直径150mm，流动相A为含有0.1％体积比三氟乙酸的水，流动相B为含有0.1％体积比三氟乙酸的乙腈，梯度洗脱(B 20-50％，洗脱时间60min)，流速600mL/min，检测波长230nm。收集主峰成分。用分析型高效液相色谱检测收集液的纯度。合并纯度大于98％的部分，得KIFGSLAFL纯品溶液。用分析型高效液相色谱检测收集液的纯度，纯度98.6％，收率45％。
分析高效液相色谱检测三氟乙酸和目标肽含量的条件是：创新通恒LC300高效液相色谱仪，C18键合硅胶(250×4.6mm，5μm)为固定相，流动相A为乙腈，流动相B为0.1mol/L磷酸二氢钠(磷酸调pH至3.0)水溶液。梯度洗脱(流动相A从5％到45％，洗脱时间20min；然后改流动相A 45％等度洗脱)，流速1mL/min。检测波长195nm(0-8min)和230nm(8-50min)。三氟乙酸和目标肽的出峰时间分别约为4.9和21min。
分析高效液相色谱检测目标肽纯度的条件是：创新通恒LC300高效液相色谱仪，C18键合硅胶(250×4.6mm，5μm)为固定相，流动相为0.1mol/L磷酸二氢钠(磷酸调pH至3.0)水溶液和乙腈的混合液(体积比7：3)。流速1mL/min。检测波长230nm。目标肽的出峰时间约为10min。
实施例3、游离KIFGSLAFL肽的制备
实施例2得到的KIFGSLAFL溶液冷却至0-5℃，搅拌下滴加5％NaOH水溶液至pH 10。减压浓缩至析出大量胶状沉淀。离心，用少量冰水洗涤。沉淀经真空干燥得白色固体，纯度98.1％。
实施例4、KIFGSLAFL醋酸盐溶液的制备
将实施例2得到的KIFGSLAFL溶液适当浓缩后用C18柱纯化，填料高度250mm，直径150mm。先用含有0.1％体积比醋酸和3％体积比乙腈的水溶液洗脱15min，流速800mL/min。然后用流动相A为含有0.1％体积比醋酸的水，流动相B为含有0.1％体积比醋酸的乙腈，梯度洗脱(B：20％-40％，洗脱时间50min)，检测波长230nm。收集主峰成分，得KIFGSLAFL醋酸盐溶液，纯度99.6％，收率90％。
实施例5、KIFGSLAFL醋酸盐无定形固体的制备
将实施例4得到的KIFGSLAFL醋酸盐溶液，用醋酸调节pH至4，减压浓缩至析出大量胶状沉淀，降温至0-5℃，离心取得沉淀，沉淀经<30℃真空干燥得白色固体。
按实施例2的分析高效液相色谱检测，醋酸出峰时间约为4.6min。测得样品中醋酸的重量百分数为5.7％。KIFGSLAFL的纯度99.5％。
X-ray衍射光谱检测条件：仪器型号：锐影(Empyrean)X-射线衍射仪；测试条件：Cu靶Kα1射线，电压40kv，电流40mA，2θ范围3°-50°，发散狭缝1/32°，防散射狭缝1/16°，防散射狭缝7.5mm，步长0.02°，每步停留时间40S。X-ray衍射光谱如附图1所示。
KBr压片法得到的IR光谱如附图2所示。
ESI质谱检测结果如图3所示，其中995.9m/z峰为M+H+，与KIFGSLAFL的分子量计算值基本一致。
实施例6、KIFGSLAFL·H2SO4的制备
将实施例2得到的KIFGSLAFL溶液冷却至0-5℃，搅拌下滴加重量比5％NaOH水溶液至pH 10。减压浓缩至析出大量胶状沉淀。离心，用少量冰水洗涤。固体用体积比50％的乙腈溶液溶解，按每含1mol E75加入0.5mol的比例加入H2SO4，搅拌均匀(pH＝6)，30℃水浴下减压旋转蒸发浓缩2～3h。冷冻干燥即成固体产品。
实施例7、KIFGSLAFL和KIFGSLAFL醋酸盐的稳定性测定
在无菌环境25℃和RH 50％下，考察以下样品的稳定性：
样品1为实施例5的无定形固体产品。样品2为实施例4的溶液用二甲基亚砜稀释至约1mg/mL，用0.2微米孔径的滤膜过滤。样品3为实施例3的固体产品。样品4为实施例3的固体产品用二甲基亚砜溶解，并稀释至约1mg/mL，用0.2微米孔径的滤膜过滤。样品5为实施例6的固体产品。用高效液相色谱检测各样品的纯度，结果如下表：
  样品1 样品2 样品3 样品4 样品5
0天 99.5％ 99.6％ 98.1％ 98.1％ 99.2％
5天 99.4％ 98.9％ 97.6％ 96.5％ 98.7％
10天 99.3％ 98.3％ 97.2％ 94.6％ 98.0％
从上表实验结果可见：现有技术的KIFGSLAFL固体(样品3)以及其DMSO溶液(样品4)的稳定性明显差于KIFGSLAFL醋酸盐无定形固体(样品1)以及其DMSO溶液(样品4)；且KIFGSLAFL醋酸盐无定形固体(样品1)的稳定性也明显优于其DMSO溶液(样品2)，以及KIFGSLAFL·H2SO4(样品5)。
实施例8、溶解性测定
小试管中，分别把实施例3、实施例5和实施例6的固体产品加到一定质量的25℃注射用水中，置于恒温摇床中振荡，观察固体溶解的情况。
溶解情况如下：
水量 实施例3样品 实施例5样品 实施例6样品
300倍 >30分钟(未全溶) <1分钟(全溶) >30分钟(未全溶)
800倍 >30分钟(未全溶) <1分钟(全溶) >30分钟(未全溶)
从上表实验结果可见：KIFGSLAFL醋酸盐无定形固体(实施例5样品)的水溶性相对于现有技术的KIFGSLAFL固体、以及KIFGSLAFL·H2SO4有大幅的提高，更易于制剂使用。
实施例9、多肽疫苗制品的制备
于无菌环境中按照实施例5的操作制备得到的KIFGSLAFL醋酸盐。精密称量(以KIFGSLAFL计1mg/份)，分装于玻璃瓶中，密闭包装，得多肽疫苗制品。
实施例10
将实施例2得到的KIFGSLAFL溶液适当浓缩后用C18柱纯化，填料高度250mm，直径150mm。用流动相A为含有0.1％体积比醋酸的水，流动相B为乙腈，梯度洗脱(B：20％-40％，洗脱时间50min)，流速800mL/min，检测波长230nm。收集主峰成分，得KIFGSLAFL的溶液经减压浓缩和冻干后得白色固体。按实施例2的HPLC检测，醋酸的重量百分比为4.8％和三氟乙酸的重量百分比为1.9％。
实施例11
将实施例1得到的KIFGSLAFL粗品按照实施例2的方法进行色谱纯化，收集主峰成分。用分析型高效液相色谱检测收集液的纯度。合并纯度大于92％的部分，得KIFGSLAFL溶液。用分析型高效液相色谱检测收集液的纯度，纯度95.1％。然后按照实施例4的色谱方法进行转盐，收集主峰成分，得KIFGSLAFL醋酸盐溶液，纯度95.3％。将得到的KIFGSLAFL醋酸盐溶液减压浓缩至干，40℃真空干燥得白色固体。总收率60％。按实施例2的HPLC检测，KIFGSLAFL的纯度94.1％。
实施例12
将实施例1得到的KIFGSLAFL粗品按照实施例2的方法进行色谱纯化，收集主峰成分。用分析型高效液相色谱检测收集液的纯度。合并纯度大于92％的部分，得KIFGSLAFL溶液。用分析型高效液相色谱检测收集液的纯度，纯度95.1％。然后按照实施例4的色谱方法进行转盐，收集主峰成分，得KIFGSLAFL醋酸盐溶液，纯度95.3％。总收率60％。然后按照实施例5的方法处理后得白色固体，为无定形KIFGSLAFL醋酸盐，纯度95.3％。
实施例13
将实施例1得到的KIFGSLAFL粗品按照实施例2的方法进行色谱纯化，收集主峰成分。用分析型高效液相色谱检测收集液的纯度。合并纯度大于96％的部分，得KIFGSLAFL溶液。用分析型高效液相色谱检测收集液的纯度，纯度97.5％。然后按照实施例4的色谱方法进行转盐，收集主峰成分，得KIFGSLAFL醋酸盐溶液，纯度98.1％。总收率45％。然后按照实施例5的方法处理后得白色固体，为无定形KIFGSLAFL醋酸盐，纯度98.0％。
因合成KIFGSLAFL过程中产生数量众多的杂质，使产业化制备高纯度 的KIFGSLAFL盐存在明显的技术难度，难以得到高纯度的单盐纯品，且如上述实施例10所述，合成产品易生成如醋酸和三氟醋酸等的混盐，不易分离纯化得到单盐的纯品。
发明人根据本领域常规分离纯化手段优选方案，如实施例11的方案，只能得到纯度在95％以下的产品，不利于产品的医药应用。然而，最终通过大量实验劳动优选的纯化方案，如实施例12和13，使产品的纯度达到95％以上，甚至可达到98％以上，克服了难以获得高纯度KIFGSLAFL盐的困难，使该品产业化及医药应用才真正成为可能。
上述实施例为本发明较佳的实施方式，但本发明的实施方式并不受上述实施例的限制，其他的任何未背离本发明的精神实质与原理下所作的改变、修饰、替代、组合、简化，均应为等效的置换方式，都包含在本发明的保护范围之内。

Claims (10)

  1. KIFGSLAFL醋酸盐，其分子式为C50H78N10O11·C2H4O2。
  2. 根据权利要求1的醋酸盐，其特征在于，所述KIFGSLAFL醋酸盐的纯度≥95％，优选≥98％，更优选≥99％。
  3. 根据权利要求1的醋酸盐，其特征在于，所述KIFGSLAFL醋酸盐为无定形固体，其X-射线衍射谱图无晶体特征的吸收峰。
  4. 根据权利要求2的醋酸盐，其特征在于，所述KIFGSLAFL醋酸盐为无定形固体，其X-射线衍射谱图无晶体特征的吸收峰。
  5. 根据权利要求1至4任一权利要求所述的醋酸盐，其特征在于，所述KIFGSLAFL醋酸盐的红外吸收在3288cm-1、3065cm-1、2958cm-1、1632cm-1、1527cm-1、1404cm-1和698cm-1处有峰。
  6. 一种多肽疫苗的药物制品，包含：权利要求1至5任一权利要求所述的KIFGSLAFL醋酸盐，它适宜用药学上可接受的溶媒重新配制为一种可注射的药用产品，通过注射途径给予患者。
  7. 根据权利要求6的制品，其特征在于，所述溶媒包括注射用水或无菌水。
  8. 一种制备权利要求1至2任一权利要求所述的KIFGSLAFL醋酸盐的方法，包括如下步骤：
    (1)、采用Fmoc固相合成方法，按照氨基酸序列(9→1)的顺序，合成KIFGSLAFL肽树脂，然后经三氟乙酸裂解，得到KIFGSLAFL粗品；
    (2)、KIFGSLAFL的纯化：将KIFGSLAFL粗品溶解，过滤，以三氟乙酸的乙腈/水溶液为流动相进行反相高效液相色谱纯化，收集主峰成分；
    (3)、转盐：将步骤(2)所得的主峰成分以醋酸的乙腈/水溶液为流动相进行反相高效液相色谱转盐，收集主峰成分；
    (4)、减压浓缩，经干燥得到。
  9. 根据权利要求8的制备方法，其特征在于，步骤(2)纯化和步骤(3) 转盐条件分别以C4、C8或C18烷基键合硅胶为固定相；柱温20-35℃；步骤(2)纯化使用流动相中三氟乙酸浓度为0.02％-0.5％(v/v)，步骤(3)转盐使用流动相中醋酸浓度为0.02％-0.5％(v/v)。
  10. 一种制备权利要求3至4任一权利要求所述的KIFGSLAFL醋酸盐的方法，其特征在于，包括：将转盐后的KIFGSLAFL醋酸盐溶液用乙酸调节至pH 4，减压浓缩至析出KIFGSLAFL醋酸盐沉淀，降温至5℃以下，离心取得沉淀，<30℃真空干燥后得到。
PCT/CN2014/087506 2013-09-26 2014-09-26 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品 WO2015043497A1 (zh)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2016518164A JP6392330B2 (ja) 2013-09-26 2014-09-26 ポリペプチドワクチンの塩及びその製造方法と該塩を含有する医薬製品
CA2925535A CA2925535A1 (en) 2013-09-26 2014-09-26 Salt of polypeptide vaccine, preparation method therefor, and pharmaceutical preparation comprising said salt
EP14850072.1A EP3050895A4 (en) 2013-09-26 2014-09-26 Salt of polypeptide vaccine, preparation method therefor, and pharmaceutical preparation comprising said salt
KR1020167007821A KR101802485B1 (ko) 2013-09-26 2014-09-26 폴리펩티드 백신 염 및 그 제조방법과 상기 염을 함유한 의약품
RU2016114322A RU2649401C2 (ru) 2013-09-26 2014-09-26 Соль пептидной вакцины, способ ее получения и фармацевтический препарат, содержащий эту соль
US15/023,805 US20160229891A1 (en) 2013-09-26 2014-09-26 Salt of polypeptide vaccine, preparation method therefor, and pharmaceutical preparation comprising said salt

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201310447114 2013-09-26
CN201310447114.6 2013-09-26

Publications (1)

Publication Number Publication Date
WO2015043497A1 true WO2015043497A1 (zh) 2015-04-02

Family

ID=52742076

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/087506 WO2015043497A1 (zh) 2013-09-26 2014-09-26 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品

Country Status (8)

Country Link
US (1) US20160229891A1 (zh)
EP (1) EP3050895A4 (zh)
JP (1) JP6392330B2 (zh)
KR (1) KR101802485B1 (zh)
CN (1) CN104513293A (zh)
CA (1) CA2925535A1 (zh)
RU (1) RU2649401C2 (zh)
WO (1) WO2015043497A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114384188A (zh) * 2021-12-28 2022-04-22 湖南中晟全肽生化有限公司 一种长肽的溶解及检测方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678093A (zh) * 2007-06-01 2010-03-24 亨利·M·杰克逊军事医学促进基金会 预防乳腺癌复发的疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018409A1 (en) * 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells
US20040121946A9 (en) * 2000-12-11 2004-06-24 John Fikes Inducing cellular immune responses to her2/neu using peptide and nucleic acid compositions
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
EP2013226A2 (en) * 2006-03-28 2009-01-14 Wockhardt Limited Processes for the preparation of octreotide
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
CA2713879C (en) * 2008-02-01 2020-01-07 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678093A (zh) * 2007-06-01 2010-03-24 亨利·M·杰克逊军事医学促进基金会 预防乳腺癌复发的疫苗

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. 58, no. 21, 1998, pages 4902 - 8
KNUTSON KL ET AL.: "Immunization of cancer patients with HER-2/neu, HLA-A2 peptide, p369-377, fesults in short-lived peptide-specific immunity", CLIN CANCER RES, vol. 8, no. 5, 2002, pages 1014 - 1018, XP055206168
RIESLAG ET AL.: "SEER Cancer Statistics Review", 1975, NATIONAL CANCER INSTITUTE
See also references of EP3050895A4
ZAKS T ET AL., IMMUNIZATION WITH A PEPTIDE EPITOPE, pages 369 - 377

Also Published As

Publication number Publication date
KR101802485B1 (ko) 2017-11-28
CA2925535A1 (en) 2015-04-02
JP2016539082A (ja) 2016-12-15
EP3050895A4 (en) 2017-03-01
CN104513293A (zh) 2015-04-15
EP3050895A1 (en) 2016-08-03
JP6392330B2 (ja) 2018-09-19
RU2649401C2 (ru) 2018-04-03
US20160229891A1 (en) 2016-08-11
RU2016114322A (ru) 2017-10-31
KR20160068749A (ko) 2016-06-15

Similar Documents

Publication Publication Date Title
JP4653840B2 (ja) メタスチン誘導体およびその用途
CN107108698A (zh) 用作免疫调节剂的大环肽
WO2009094850A1 (en) Recombinant ganoderma lucidium immunomodulatory protein (rlz-8) and uses thereof
US20090105152A1 (en) Metastin derivatives and use thereof
KR20080033331A (ko) 종양 치료제
JP2010507565A (ja) メタスチン誘導体およびその用途
WO2009131191A1 (ja) メタスチン誘導体およびその用途
WO2018108154A1 (zh) 多粘菌素衍生物及其制备方法和应用
Gonçalves et al. Design, synthesis, and evaluation of original carriers for targeting vascular endothelial growth factor receptor interactions
EP0531080A2 (en) Peptide inhibitors of human papilloma virus protein binding to retinoblastoma gene protein
KR20200127922A (ko) 신규한 올리고펩티드 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
US20090093615A1 (en) Metastin derivatives and use thereof
CN111040020A (zh) 一种烯烃硫醚类订书肽及其制备方法与应用
WO2015043497A1 (zh) 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
CN107936109B (zh) 衍生自sage1的肿瘤抗原短肽
CN109248324B (zh) GnRH类似物－抗肿瘤药物偶联物、其制备方法及用途
WO2023214576A1 (ja) Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
KR20130060267A (ko) 펩타이드계 물질의 결정체 및 그의 제조방법과 용도
CN108218977B (zh) 源自于肿瘤抗原sage1的短肽
CN113045627B (zh) 一种抗菌多肽sa-2及其制备方法和应用
KR20230160321A (ko) 면역조정제
Yu et al. Hydrocarbon stapling modification of peptide alyteserin‐2a: Discovery of novel stapled peptide antitumor agents
WO2015096725A1 (zh) 端基具有亲脂性结构的线性脂肽、其制备方法及用途
KR101472903B1 (ko) T 세포 활성 억제 펩타이드 및 이의 용도
CN114524870A (zh) 源自于ssx2抗原的短肽

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2925535

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15023805

Country of ref document: US

ENP Entry into the national phase

Ref document number: 20167007821

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2016518164

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14850072

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2014850072

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014850072

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2016114322

Country of ref document: RU

Kind code of ref document: A